---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-25-000039"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:27:48.339232+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pacira BioSciences: 2024 record rev $701M, GAAP net loss $99.6M on $163M impairment; FY2025 rev guide $725M-$765M

## Summary
- Q4 2024 rev $187.3M (+3% YoY); full-year rev $701.0M (+4%); EXPAREL $549M, ZILRETTA $118M, iovera $22.8M.
- Full-year GAAP net loss $99.6M ($2.15 loss/share) includes $163.2M goodwill impairment; adjusted EBITDA $223.9M (+4%).
- Non-GAAP net income $157.7M ($3.20 diluted); Q4 non-GAAP net income $44.3M ($0.91 diluted).
- Acquired remaining 81% of GQ Bio for ~$32M net; adds genetic medicine platform, eliminates future milestones.
- FY2025 guidance: rev $725-765M, non-GAAP gross margin 76-78%, R&D $90-105M, SG&A $290-320M.

## SEC filing metadata
- accession: 0001396814-25-000039
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000039/0001396814-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000039/pcrx-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-25-000039
- JSON: https://secwatch.observer/filing/0001396814-25-000039.json
- Plain text: https://secwatch.observer/filing/0001396814-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.